Form 4 for CLPT ClearPoint Neuro, Inc.
Accepted 2023-07-05 00:00:00 ET · period of report 2023-06-30 · accession 0001285550-23-000083 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-07-05 | 2023-06-30 | CLPT | STIGALL L. JEREMY | GM, Biologics, Drug Delivery | A - Grant | $6.15 | +2,682 | 44.4K | +6% | +$16.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-30 | A | A | 2,682 | $6.15 | 44,376 | D | — | — | (F1) The reporting person is voluntarily reporting the acquisition of the Issuer's common stock pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2023 through June 30, 2023. In accordance with the ESPP, these shares were purchased at the lesser of 85% of the fair market value on either the first day or last day of the purchase period. |